Skip to main content
. Author manuscript; available in PMC: 2022 Dec 21.
Published in final edited form as: Thorax. 2022 Feb 24;78(1):41–49. doi: 10.1136/thoraxjnl-2021-218068

Table 2.

Prevalence of respiratory and allergic outcomes among 303 children from the ISA Population at age 5, Matina County, Costa Rica 2015–2016

Type of outcome Outcome N %

Respiratory Ever wheeze (symptom of asthma) 97 32
Current* wheeze (symptom of asthma) 62 20
Current symptoms of severe asthma 33 11
Ever doctor-diagnosed asthma 37 12
Current dry cough 118 39
Ever LRTI 49 16
Current LRTI 15 5
Allergic Ever nasal allergies (allergic rhinitis) 67 22
Current nasal allergies (allergic rhinitis) 63 21
Current allergic rhinoconjunctivitis 42 14
Ever itchy rash (symptom of eczema) 52 17
Current itchy rash (symptom of eczema) 39 13
Ever doctor-diagnosed eczema 21 7
Current medication for eczema 8 3
*

Past 12 months.

Selected for epidemiological analysis.

≥4 attacks of wheeze, or >1 night per week sleep disturbance from wheeze, or wheeze affecting speech in the past 12 months.

ISA, Infants’ Environmental Health Study; LRTI, lower respiratory tract infection.